FUNDAMENTALS |
MarketCap: |
0.0673 mill
|
EPS: |
-0.310
|
P/E: |
-0.0100
|
Earnings Date: |
May 12, 2023 |
SharesOutstanding: |
42.08 mill
|
Avg Daily Volume: |
0.0013 mill
|
RATING
2024-04-18 |
B+
|
Neutral
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Sell
|
|
DE: |
Neutral
|
|
P/E: |
Neutral
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | | | | | | |
Asset | | | | | | |
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.0100 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
0.00x
|
Company: PE -0.0100 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0006 - 0.0026
( +/- 62.50%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2021-11-23 | Greenspan Ira Scott | Sell | 3 000 000 | W Warrants |
2021-11-23 | Lamstein Joshua R | Sell | 3 000 000 | W Warrants |
2021-06-01 | Hopper Paul | Buy | 6 333 | Common Stock |
2020-12-15 | Hopper Paul | Buy | 0 | Common Stock |
2020-12-15 | Hopper Paul | Sell | 0 | Common Stock |
INSIDER POWER |
0.00
|
Last
55 transactions |
Buy:
2 180 518 | Sell:
6 965 870 |
Forecast:
15:05 - $0.0020
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
Volume Signals |
Price |
$0.0016 (0.00% )
|
Volume |
0.0000 mill
|
Avg. Vol. |
0.0013 mill
|
% of Avg. Vol |
2.16 %
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SCPS
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.